title: Lexipafant inhibits postsurgical adhesion formation.
abstract: BACKGROUND
  PAF and its antagonists have been studied in the pathophysiology of various inflammatory conditions. This study investigates the effects of a platelet activating factor antagonist, lexipafant, on peritoneal adhesion formation and wound healing.
  
  
  METHODS
  Forty-eight Wistar albino rats (300-350 g) were divided into four equal groups; adhesion-induced lexipafant (AL), adhesion-induced saline (AS), sham-operated lexipafant (SL), and sham-operated saline (SS). All rats underwent a midline laparotomy under sterile conditions. The anterior wall of the left uterine horn was scraped to cause hemorrhages in adhesion-induced groups. Following peritoneal injections of either saline or lexipafant, the incisions were closed in layers. On the 14th day, the rats were killed and adhesions were scored from 0 (none) to 4 (dense). Tissue samples from the adhesions and the left horn of uterus were examined biochemically for hydroxyproline content, and serum IL-6 levels were determined.
  
  
  RESULTS
  The adhesion formation score was significantly increased in the AS group compared to the SL and AL groups (P < 0.001). The IL-6 levels of the AS group were higher than those of the other groups (P < 0.05). There was no significant difference in hydroxyproline content between groups (P > 0.05).
  
  
  CONCLUSIONS
  Lexipafant plays a role in the prevention of adhesion formation without affecting wound healing.
authors.affiliation: Department of Surgery, Adnan Menderes University, Aydin, Turkey.
authors.forename: Hedef
authors.initials: H
authors.lastname: Ozgün
authors.forename: Mehmet Hakan
authors.initials: MH
authors.lastname: Cevikel
authors.forename: Leyla Didem
authors.initials: LD
authors.lastname: Kozaci
authors.forename: Serhan
authors.initials: S
authors.lastname: Sakarya
mesh_terms: D000818:Animals; D005260:Female; D006909:Hydroxyproline / Q000032:analysis; D007093:Imidazoles / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010532:Peritoneal Diseases / Q000517:prevention & control*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D011183:Postoperative Complications / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D000267:Tissue Adhesions / Q000517:prevention & control*; D014599:Uterus / Q000737:chemistry; D014945:Wound Healing / Q000187:drug effects
chemical_list: D007093:Imidazoles; D015850:Interleukin-6; D010972:Platelet Activating Factor; D007930:Leucine; C103289:lexipafant; D006909:Hydroxyproline